Siemens Healthineers Shares Plunge to 52-Week Low as Tariff Headwinds and China Slowdown Bite

Siemens Healthineers hits 52-week low as US tariffs, currency headwinds, and China slump slash earnings; new CTO bets on AI amid looming German healthcare cuts.

Investors are punishing Siemens Healthineers with a ferocity that stands in stark contrast to management's confident public stance. The stock touched a fresh 52-week trough of €35.20 on Friday, extending its year-to-date slide to roughly 20% and leaving it trading at a chasm-like discount to the €53 average analyst price target. The previous session saw the shares dip to €35.61, underscoring a persistent downward trajectory that has wiped out gains from last summer's highs.

A Triple Threat to Earnings

The sell-off is rooted in a confluence of operational pressures that are squeezing margins from multiple angles. US tariffs are expected to carve approximately €400 million out of adjusted operating profit this fiscal year, while unfavorable currency movements will subtract another €200 million to €250 million. Combined, these external shocks are costing the medical technology group up to half a billion euros in earnings power.

The pain is compounded by a pronounced slowdown in China, where an anti-corruption campaign has disrupted sales channels. The diagnostics division, already the weakest link in the portfolio, recorded a noticeable decline in the first quarter. Management has tempered expectations for the current quarter, warning that revenue growth will fall short of the regular target range. A recovery is not anticipated until 2027, when the company forecasts annual growth of roughly 5% in the Chinese market.

Home Market Risks Add to the Gloom

Adding to the uncertainty, the German cabinet is scheduled to decide on April 29 whether to push through €20 billion in cuts to statutory health insurance. Such a move would squeeze hospital budgets across the country, directly threatening demand for Siemens Healthineers' high-end imaging systems and laboratory diagnostics. The timing could hardly be worse, coming just days before the company's second-quarter earnings release on May 7.

A New CTO and a Bet on AI

In an effort to chart a technological escape from the operational headwinds, the company is doubling down on artificial intelligence. Martin Stumpe, a veteran of Google Brain and Danaher, will assume the role of Chief Technology Officer on June 1, replacing Peter Schardt. Stumpe has already floated concepts for digital patient models, and the company is showcasing its revamped angiography portfolio at the ECIO conference in Basel, where AI algorithms are being deployed to automate motion correction during liver cancer embolization procedures.

The radiopharmaceuticals segment is also getting a boost. A new supply agreement with Radiopharm Theranostics will secure production of the PET imaging agent RAD101 for an upcoming US approval study. The drug, used to diagnose brain metastases, has already received Fast-Track designation from the FDA.

The €13.9 Billion Question

The strategic spotlight, however, remains fixed on the planned separation from parent Siemens. The industrial conglomerate intends to put a direct spin-off of its Healthineers stake—currently just over two-thirds of the shares—to a vote at its February 2027 annual general meeting. Under the plan, 30% of Healthineers stock would be transferred directly to Siemens shareholders.

A critical piece of the puzzle fell into place when Moody's assigned Healthineers an A3 credit rating, paving the way for the company to issue its own bonds and finance itself independently. But the balance sheet carries a daunting €13.9 billion in debt, currently guaranteed by Siemens. Once the safety net is removed post-spin-off, Healthineers will have to shoulder the full cost of servicing that debt on its own.

Analysts Hold Their Ground

Despite the stock's descent, the analyst community remains broadly bullish. Jefferies maintains a Buy rating with a €60 price target, while the consensus view still points to significant upside from current levels. The May 7 earnings report will be the first real test of whether the imaging and diagnostics businesses can weather the storm. Management has reaffirmed its full-year guidance for adjusted earnings of at least €2.20 per share, but with the stock plumbing new lows, the market is clearly demanding proof, not promises.